Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Efficacy and Safety of Anti LINGO-1 for the Treatment of Relapsing Forms of Multiple Sclerosis: Design of the Phase 2 SYNERGY Trial
Multiple Sclerosis
(-)
154
Authors/Disclosures
Diego Cadavid, MD, FÂ鶹´«Ã½Ó³»­ (Verge Genomics)
PRESENTER 		Dr. Cadavid has received personal compensation for serving as an employee of Verge Genomics. Dr. Cadavid has received personal compensation for serving as an employee of Vertex Pharmaceuticals. Dr. Cadavid has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. Cadavid has or had stock in Verge Genomics.Dr. Cadavid has or had stock in Vertex Pharmaceuticals.
Glenn A. Phillips, PhD Dr. Phillips has received personal compensation for serving as an employee of argenx. Dr. Phillips has stock in argenx.
Giancarlo Logroscino, MD, PhD, FÂ鶹´«Ã½Ó³»­ (University of Bari) Dr. Logroscino has nothing to disclose.
Tuan Dong-Si, MD No disclosure on file
Jonathan Tran No disclosure on file
Lei Xu, MD (FDA) No disclosure on file